NeuTec Pharma Ltd.
Manchester
M13 9WL, United Kingdom (Map) Phone: +44-161-276-8827
Fax: +44-161-276-8826
http://www.neutecpharma.com
Overview
NeuTec wants to make visiting the hospital an experience that lessens patient dangers. The biopharmaceutical company identifies and compares antibodies produced by patients who recover from infections (acquired in hospitals) to those produced by patients who die. Then, using its FabTec technology, it develops genetically recombinant antibodies, or "grabs," to treat patients with life-threatening infections. The company's two leading candidates, Mycograb, which targets a fungus in the mouth and skin, and Aurograb, which targets bacterial infections, are in clinical trials in the UK. Mycograb also is in clinical trials in the US.
Key Numbers from Hoover's UK
Key financials for NeuTec Pharma Ltd.
| Company Type | Subsidiary of Novartis |
|---|---|
| Fiscal Year-End | June |
| Sales (mil.) | £4.0 |
| Employees | 11 |
Key People from Hoover's UK
Key people and executives for NeuTec Pharma Ltd.
| Chairman | Anthony F. (Tony) Martin (Subscribers see complete biographies -- view sample)
Connect to this executive |
|---|---|
| CEO | Prof James P. Burnie Connect to this executive |
| Director, Finance and Secretary | Andrew P. King Connect to this executive |
Top Competitors from Hoover's UK
Top competitors of NeuTec Pharma Ltd.
There are 6 competitors for NeuTec; see more.
